Results 131 to 140 of about 53,199 (230)

Racial differences in multiple myeloma survival: Associations with stem cell transplantation, insurance, and Medicaid expansion

Cancer, Volume 132, Issue 17, 1 September 2026.
ABSTRACT Background At the population level, Black patients with multiple myeloma (MM) may experience worse survival than White patients. The authors examined how autologous stem cell transplantation (ASCT), insurance, and Medicaid expansion relate to racial differences in real‐world overall survival (rwOS). Methods Data from 4932 patients with MM (24%
F. Lennie Wong, Scott R. Goldsmith, Kimlin Ashing, Amrita Krishnan, Michael A. Rosenzweig, Saro H. Armenian   +5 more
wiley   +1 more source

Oncogenic KRAS Rewires Stress Granule Dynamics: Mechanisms and Therapeutic Opportunities

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 9, September 2026.
ABSTRACT Stress granules (SGs) are dynamic, membrane‐less structures that form in response to various cellular stresses, including metabolic, oxidative, and therapeutic challenges. They function as adaptive hubs and reorganize protein synthesis and signaling networks to help cells survive under stress. In cancer, these condensates are often hijacked to
Msimisi Ndzinisa, Birhanetensay Masresha Altaye, Yuh‐Pyng Sher   +2 more
wiley   +1 more source

Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines

BackgroundThe proteasome inhibitor bortezomib is one of the primary therapies used for the haematological malignancy multiple myeloma (MM). However, intrinsic or acquired resistance to bortezomib, via mechanisms that are not fully elucidated, is a ...
Dold, Sandra M, Hewett, D.R., Mrozik, K.M., Zannettino, Andrew, Dold, S.M., Panagopoulos, V., Mrozik, Krzysztof M., Engelhardt, Monika, Panagopoulos, Vasilios, Spencer, Andrew, Wallington-Gates, Craig T, Dold, Sandra Maria, Mrozik, Krzysztof M, Engelhardt, M., Vandyke, Kate, Hewett, Duncan R., Zannettino, A.C.W., Wallington-Gates, C.T., Hewett, Duncan R, Zannettino, Andrew CW, Wallington-Gates, Craig T., Spencer, A., Vandyke, K., Zeissig, M.N., Zeissig, Mara, Zeissig, Mara N   +25 more
core   +1 more source

Protein Posttranslational Modifications in Immunity: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 9, September 2026.
Protein posttranslational modifications, including phosphorylation, ubiquitination, SUMOylation, acetylation, methylation, glycosylation, and other new types, dynamically regulate antigen presentation and recognition, immune signal transduction, antibody production and class switching, immune contraction, immune memory establishment, as well as immune ...
Yuxing Yao, Jinxiu Qian, Qiqiong Liu, Wanting Ye, Ying Xing, Xiuyun Bai, Rongjun Deng, Jue Yang, Cheng Lu, Cheng Xiao, Yuanyan Liu   +10 more
wiley   +1 more source

Proteasome inhibition alleviates proteinuria in Lmx1b knock-in mice with dysfunctional LIM domains. [PDF]

Nat Commun
Hermens J, Lucke L, Pieles O, Maier O, Othmen H, Burghardt T, Schmidt A, Moser M, Madej MG, Schwartz U, Zaparty M, Witzgall R.   +11 more
europepmc   +1 more source

Prognostic significance of CD56 expression in newly diagnosed multiple myeloma and its correlation with clinicopathological features. [PDF]

Front Oncol
Pei P, Lv J, Zheng B, Lv K, Bai J, Li L, Song Q, Lu Z, Xu H, Zhang Y.   +9 more
europepmc   +1 more source

Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis

British Journal of Haematology, Volume 209, Issue 3, Page 874-886, September 2026.
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, Cristina Napoli, Lucia Fiorillo, Chiara Callerame, Mario Garritano, Alessio Bulotta, Maha Munir, Giulia Pensabene, Emiliano Barbieri, Alberto Bavieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, Stefano Luminari   +14 more
wiley   +1 more source

Graphene Oxide Modulates ROS Production and Apoptotic Responses to Bortezomib in Human Glioblastoma Cells: An In Vitro Study. [PDF]

Cells
Krętowski R, Jabłońska-Trypuć A, Tyszka N, Kalita J, Cechowska-Pasko M.   +4 more
europepmc   +1 more source

The selective degradation of PDE4B shortform, using a PROTAC, leads to inhibition of several hallmarks of cancer in HCT116 cells

British Journal of Pharmacology, Volume 183, Issue 18, Page 5516-5540, September 2026.
Background and Purpose Colorectal cancer is one of the most prevalent cancers worldwide, and novel precision medicine approaches are rapidly improving patient outcomes. Phosphodiesterase 4B (PDE4B) is a member of an enzyme family (PDE4) that hydrolyses intracellular cAMP to control spatial and temporal signalling cues.
Alina Zorn, John Daniel Pediani, Madihah Hussain, Jiayue Ling, Elaine Brown, Igor Belka, Eduardo Torres, Cathy Swindlehurst, Kyle Chan, David Stirling, George S. Baillie, Yuan Yan Sin   +11 more
wiley   +1 more source

Low-dose daratumumab and bortezomib for the treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a case report. [PDF]

Front Med (Lausanne)
Zhu J, Zhang L, Zhao H, Tian L, Pei H, Li S, Xing L.   +6 more
europepmc   +1 more source